Sustained-release Drug Delivery Systems for the Treatment of Glaucoma

Overview

Journal Int J Ophthalmol

Specialty Ophthalmology

Date 2021 Jan 20

PMID 33469497

Citations 18

Authors

Natasha P Kesav

Cara E Capitena Young

Monica K Ertel

Leonard K Seibold

Malik Y Kahook

Affiliations

Soon will be listed here.

Abstract

Glaucoma, a leading cause of irreversible blindness, affects more than 64 million people worldwide and is expected to grow in number due to the aging global population and enhanced methods of detection. Although topical therapies are often effective when used as prescribed, the drawbacks of current medical management methods include poor patient adherence, local and systemic side effects, and in some cases, limited therapeutic efficacy. Novel ocular drug delivery platforms promise to deliver differentiated drug formulations with targeted delivery leveraging patient-independent administration. Several platforms are in various stages of development with promising pre-clinical and clinical data. The Bimatoprost Sustained Release (SR) intracameral implant was approved in the United States in March of 2020, making it the first long-term injectable therapy available for the treatment of glaucoma. This review aims to provide an update on novel sustained release drug delivery systems that are available today as well as those that might be commercialized in coming years.

Citing Articles

Persistent bilateral sclerouveitis following bimatoprost implantation and removal.

Jiao C, Prabakaran G, Berk T, Hossain H, Arepalli S Am J Ophthalmol Case Rep. 2025; 37():102240.

PMID: 39839914 PMC: 11750282. DOI: 10.1016/j.ajoc.2024.102240.

Emerging trends in long-acting sustained drug delivery for glaucoma management.

So Y, Mishra D, Gite S, Sonawane R, Waite D, Shaikh R Drug Deliv Transl Res. 2025; .

PMID: 39786666 DOI: 10.1007/s13346-024-01779-4.

Managing Ocular Surface Disease in Glaucoma Treatment: A Systematic Review.

Kemer O, Mekala P, Dave B, Kooner K Bioengineering (Basel). 2024; 11(10).

PMID: 39451386 PMC: 11504873. DOI: 10.3390/bioengineering11101010.

Drug Delivery Systems for Glaucoma: A Narrative Review.

Fea A, Vallino V, Cossu M, Marica V, Novarese C, Reibaldi M Pharmaceuticals (Basel). 2024; 17(9).

PMID: 39338326 PMC: 11435076. DOI: 10.3390/ph17091163.

Nanomedicine in glaucoma treatment; Current challenges and future perspectives.

Iqbal H, Razzaq A, Zhou D, Lou J, Xiao R, Lin F Mater Today Bio. 2024; 28:101229.

PMID: 39296355 PMC: 11409099. DOI: 10.1016/j.mtbio.2024.101229.

References

Kumari A, Sharma P, Garg V, Garg G . Ocular inserts - Advancement in therapy of eye diseases. J Adv Pharm Technol Res. 2012; 1(3):291-6. PMC: 3255407. DOI: 10.4103/0110-5558.72419. View

Tyson S, Bafna S, Gira J, Goldberg D, Jones J, Jones M . Multicenter randomized phase 3 study of a sustained-release intracanalicular dexamethasone insert for treatment of ocular inflammation and pain after cataract surgery. J Cataract Refract Surg. 2018; 45(2):204-212. DOI: 10.1016/j.jcrs.2018.09.023. View

Ozdemir S, Wong T, Allingham R, Finkelstein E . Predicted patient demand for a new delivery system for glaucoma medicine. Medicine (Baltimore). 2017; 96(15):e6626. PMC: 5403112. DOI: 10.1097/MD.0000000000006626. View

Koo E, Hou J, Keenan J, Stamper R, Jeng B, Han Y . Effects of Glaucoma Tube Surgery on Corneal Endothelial Cells: A Review. Eye Contact Lens. 2015; 42(4):221-4. DOI: 10.1097/ICL.0000000000000171. View

Seal J, Robinson M, Burke J, Bejanian M, Coote M, Attar M . Intracameral Sustained-Release Bimatoprost Implant Delivers Bimatoprost to Target Tissues with Reduced Drug Exposure to Off-Target Tissues. J Ocul Pharmacol Ther. 2018; 35(1):50-57. PMC: 6354606. DOI: 10.1089/jop.2018.0067. View

Singh R, Ichhpujani P, Thakur S, Jindal S . Promising therapeutic drug delivery systems for glaucoma: a comprehensive review. Ther Adv Ophthalmol. 2020; 12:2515841420905740. PMC: 7074511. DOI: 10.1177/2515841420905740. View

Wong T, Novack G, Natarajan J, Ho C, Htoon H, Venkatraman S . Nanomedicine for glaucoma: sustained release latanoprost offers a new therapeutic option with substantial benefits over eyedrops. Drug Deliv Transl Res. 2015; 4(4):303-9. DOI: 10.1007/s13346-014-0196-9. View

Macoul K . Pilocarpine ocusert system for sustained control of ocular hypertension. Arch Ophthalmol. 1975; 93(8):587-90. DOI: 10.1001/archopht.1975.01010020571003. View

Craven E, Walters T, Christie W, Day D, Lewis R, Goodkin M . 24-Month Phase I/II Clinical Trial of Bimatoprost Sustained-Release Implant (Bimatoprost SR) in Glaucoma Patients. Drugs. 2019; 80(2):167-179. PMC: 7007425. DOI: 10.1007/s40265-019-01248-0. View

10.

Lee S, Burke J, Shen J, Almazan A, Orilla W, Hughes P . Bimatoprost sustained-release intracameral implant reduces episcleral venous pressure in dogs. Vet Ophthalmol. 2018; 21(4):376-381. DOI: 10.1111/vop.12522. View

11.

Manickavasagam D, Wehrung D, Chamsaz E, Sanders M, Bouhenni R, Crish S . Assessment of alkoxylphenacyl-based polycarbonates as a potential platform for controlled delivery of a model anti-glaucoma drug. Eur J Pharm Biopharm. 2016; 107:56-66. DOI: 10.1016/j.ejpb.2016.06.012. View

12.

Bourcier T, Thomas F, Borderie V, Chaumeil C, Laroche L . Bacterial keratitis: predisposing factors, clinical and microbiological review of 300 cases. Br J Ophthalmol. 2003; 87(7):834-8. PMC: 1771775. DOI: 10.1136/bjo.87.7.834. View

13.

Ciolino J, Ross A, Tulsan R, Watts A, Wang R, Zurakowski D . Latanoprost-Eluting Contact Lenses in Glaucomatous Monkeys. Ophthalmology. 2016; 123(10):2085-92. PMC: 8519348. DOI: 10.1016/j.ophtha.2016.06.038. View

14.

Brandt J, Sall K, DuBiner H, Benza R, Alster Y, Walker G . Six-Month Intraocular Pressure Reduction with a Topical Bimatoprost Ocular Insert: Results of a Phase II Randomized Controlled Study. Ophthalmology. 2016; 123(8):1685-1694. DOI: 10.1016/j.ophtha.2016.04.026. View

15.

Lewis R, Christie W, Day D, Craven E, Walters T, Bejanian M . Bimatoprost Sustained-Release Implants for Glaucoma Therapy: 6-Month Results From a Phase I/II Clinical Trial. Am J Ophthalmol. 2016; 175:137-147. DOI: 10.1016/j.ajo.2016.11.020. View

16.

Hsu K, Carbia B, Plummer C, Chauhan A . Dual drug delivery from vitamin E loaded contact lenses for glaucoma therapy. Eur J Pharm Biopharm. 2015; 94:312-21. DOI: 10.1016/j.ejpb.2015.06.001. View

17.

Peng C, Kim J, Chauhan A . Extended delivery of hydrophilic drugs from silicone-hydrogel contact lenses containing vitamin E diffusion barriers. Biomaterials. 2010; 31(14):4032-47. DOI: 10.1016/j.biomaterials.2010.01.113. View

18.

Sulley A, Young G, Hunt C, McCready S, Targett M, Craven R . Retention Rates in New Contact Lens Wearers. Eye Contact Lens. 2017; 44 Suppl 1:S273-S282. DOI: 10.1097/ICL.0000000000000402. View

19.

Wong I, Teoh S, Yeoh A, Lingam G . Sustained-release ganciclovir implant as prophylaxis for cytomegalovirus retinitis in a child undergoing bone marrow transplantation. Eye (Lond). 2013; 27(7):890-1. PMC: 3709400. DOI: 10.1038/eye.2013.81. View

20.

Robin A, Novack G, Covert D, Crockett R, Marcic T . Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol. 2007; 144(4):533-40. DOI: 10.1016/j.ajo.2007.06.012. View